CA3143417A1 - Methylthioninium as enhancers of the cognitive function - Google Patents
Methylthioninium as enhancers of the cognitive function Download PDFInfo
- Publication number
- CA3143417A1 CA3143417A1 CA3143417A CA3143417A CA3143417A1 CA 3143417 A1 CA3143417 A1 CA 3143417A1 CA 3143417 A CA3143417 A CA 3143417A CA 3143417 A CA3143417 A CA 3143417A CA 3143417 A1 CA3143417 A1 CA 3143417A1
- Authority
- CA
- Canada
- Prior art keywords
- therapeutic use
- compound
- acid
- lmtm
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/34—Coverings or external coatings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2203/00—Decoration means, markings, information elements, contents indicators
- B65D2203/02—Labels
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Mechanical Engineering (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Composite Materials (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909454.9A GB201909454D0 (en) | 2019-07-01 | 2019-07-01 | Enhancers |
| GB1909454.9 | 2019-07-01 | ||
| PCT/EP2020/068229 WO2021001306A1 (en) | 2019-07-01 | 2020-06-29 | Methylthioninium as enhancers of the cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3143417A1 true CA3143417A1 (en) | 2021-01-07 |
Family
ID=67539959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3143417A Pending CA3143417A1 (en) | 2019-07-01 | 2020-06-29 | Methylthioninium as enhancers of the cognitive function |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220330594A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3989977A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7686581B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220028045A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114096254A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020298737B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021025330A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143417A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201909454D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289341A (cg-RX-API-DMAC7.html) |
| MX (1) | MX428499B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021001306A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY162313A (en) | 2006-07-11 | 2017-05-31 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| BR112021000802A2 (pt) | 2018-07-26 | 2021-04-13 | Wista Laboratories Ltd. | Dosagem otimizada de diaminofenotiazinas em populações |
| KR102856378B1 (ko) | 2022-09-30 | 2025-09-08 | 주식회사 젬백스앤카엘 | 4r 타우병증의 치료 또는 예방용 펩티드 |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
| KR20240176447A (ko) | 2023-06-15 | 2024-12-24 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이의 용도 |
| KR102800994B1 (ko) | 2023-11-06 | 2025-04-29 | 주식회사 엘지에너지솔루션 | 무음극 코팅층 및 이를 포함하는 전고체 전지 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| AU2008265045B2 (en) * | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| PT2954932T (pt) | 2007-10-03 | 2018-12-12 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
| KR101888713B1 (ko) | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| EP2705841A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
-
2019
- 2019-07-01 GB GBGB1909454.9A patent/GB201909454D0/en not_active Ceased
-
2020
- 2020-06-29 AU AU2020298737A patent/AU2020298737B2/en active Active
- 2020-06-29 US US17/620,956 patent/US20220330594A1/en not_active Abandoned
- 2020-06-29 BR BR112021025330A patent/BR112021025330A2/pt unknown
- 2020-06-29 KR KR1020227003214A patent/KR20220028045A/ko not_active Ceased
- 2020-06-29 CN CN202080048926.1A patent/CN114096254A/zh active Pending
- 2020-06-29 JP JP2021577642A patent/JP7686581B2/ja active Active
- 2020-06-29 EP EP20735367.3A patent/EP3989977A1/en active Pending
- 2020-06-29 MX MX2021015289A patent/MX428499B/es unknown
- 2020-06-29 WO PCT/EP2020/068229 patent/WO2021001306A1/en not_active Ceased
- 2020-06-29 CA CA3143417A patent/CA3143417A1/en active Pending
-
2021
- 2021-12-23 IL IL289341A patent/IL289341A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114096254A (zh) | 2022-02-25 |
| KR20220028045A (ko) | 2022-03-08 |
| JP7686581B2 (ja) | 2025-06-02 |
| MX2021015289A (es) | 2022-01-18 |
| US20220330594A1 (en) | 2022-10-20 |
| EP3989977A1 (en) | 2022-05-04 |
| AU2020298737B2 (en) | 2026-03-05 |
| GB201909454D0 (en) | 2019-08-14 |
| WO2021001306A1 (en) | 2021-01-07 |
| MX428499B (es) | 2025-11-13 |
| JP2022539185A (ja) | 2022-09-07 |
| IL289341A (en) | 2022-02-01 |
| AU2020298737A1 (en) | 2022-02-24 |
| BR112021025330A2 (pt) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020298737B2 (en) | Methylthioninium as enhancers of the cognitive function | |
| Baddeley et al. | Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for alzheimer’s disease | |
| Yabuki et al. | Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice | |
| AU2017318333B2 (en) | Treatment of dementia | |
| Bai et al. | Ammonia induces the mitochondrial permeability transition in primary cultures of rat astrocytes | |
| EP2167095B1 (en) | Phenothiazine compounds for treating mild cognitive impairment | |
| Miyoshi et al. | Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions | |
| CN108420819A (zh) | 用于治疗神经障碍的新组合物 | |
| AU2010282509B2 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| Riederer et al. | Iron in central nervous system disorders | |
| US20230031369A1 (en) | Therapeutic interactions of leucomethylthioninium | |
| AU2020300792B2 (en) | Methylthioninium for use in the treatment of synaptopathies | |
| US20140045886A1 (en) | Laquinimod for treatment of gaba mediated disorders | |
| RU2824584C2 (ru) | Метилтиониний в качестве усилителя когнитивной функции | |
| RU2834773C2 (ru) | Терапевтические взаимодействия лейкометилтиониния | |
| Ligsay et al. | Overview of targeted double-blind, placebo-controlled clinical trials in fragile X syndrome | |
| HK40003690B (en) | Treatment of dementia | |
| HK1136965A (en) | Phenothiazine compounds for treating mild cognitive impairment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240912 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240912 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241003 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241021 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241021 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241021 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250331 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250512 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250512 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250703 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260708 |